Sea anemone cytolysins as toxic components of immunotoxins

Toxicon

Volumn 54, Issue 8, 2009, Pages 1206-1214

  Tejuca, Mayra ^a   Anderluh, Gregor ^b   Dalla Serra, Mauro ^c  

^a UNIVERSITY OF HAVANA   (Cuba)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c CNR   (Italy)

Author keywords

Actinoporin; Cancer; Immunotoxin; Pore forming toxin; Sea anemone cytolysin

Indexed keywords

CYTOLYSIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PARASITE ANTIGEN; PORE FORMING CYTOTOXIC PROTEIN; PROTEINASE; SEA ANEMONE TOXIN; TUMOR ANTIGEN;

AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GIARDIA DUODENALIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SEA ANEMONE;

ANIMALS; CELL MEMBRANE; CYTOTOXINS; GIARDIA; HUMANS; IMMUNOTOXINS; SEA ANEMONES;

ACTINIARIA; GIARDIA INTESTINALIS;

EID: 70350620010     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.02.025     Document Type: Article

References (57)

1. Abi-Habib R.J., Singh R., Liu S., Bugge T.H., Leppla S.H., and Frankel A.E. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Molecular Cancer Therapeutics 5 (2006) 2556-2562
2. Al yahyaee S.A.S., and Ellar D.J. Cell targeting of a pore-forming toxin, CytA ë-endotoxin from Bacillus thuringiensis subspecies israelensis, by conjugating CytA with anti-thy 1 monoclonal antibodies and insulin. Bioconjugate Chemistry 7 (1996) 451-460
3. Alvarez C., Dalla Serra M., Potrich C., Bernhart I., Tejuca M., Martinez D., Pazos I.F., Lanio M.E., and Menestrina G. Effects of lipid composition on membrane permeabilization by sticholysin I and II, two cytolysins of the sea anemone Stichodactyla helianthus. Biophysical Journal 80 (2001) 2761-2774
4. Anderluh G., Barlic A., Podlesek Z., Macek P., Pungercar J., Gubensek F., Zecchini M., Dalla Serra M., and Menestrina G. Cysteine-scanning mutagenesis of an eukaryotic pore-forming toxin from sea anemone: topology in lipid membranes. European Journal of Biochemistry 263 (1999) 128-136
5. Anderluh G., Dalla Serra M., Viero G., Guella G., Macek P., and Menestrina G. Pore formation by equinatoxin II, a eukaryotic protein toxin, occurs by induction of non-lamellar lipid structures. Journal of Biological Chemistry 278 (2003) 45216-45223
6. Anderluh G., and Lakey J.H. Lipid interactions of alpha-helical protein toxins. In: Tamm L.K. (Ed). Protein-Lipid Interactions: From Membrane Domains to Cellular Networks (2005), Wiley-VCH, Weinheim, Germany 141-162
7. Anderluh G., and Menestrina G. Pore-forming proteins from sea anemones and the construction of immunotoxins for selective killing of harmful cells. In: Fingerman M. (Ed). Bio-Organic Compounds: Chemistry and Biomedical Applications (2001), Science Publishers, Inc., Enfield (NH), USA 131-148
8. Anderluh G., Razpotnik A., Podlesek Z., Macek P., Separovic F., and Norton R.S. Interaction of the eukaryotic pore-forming cytolysin equinatoxin II with model membranes: 19F NMR studies. Journal of Molecular Biology 347 (2005) 27-39
9. Andreasen P.A., Egelund R., and Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences 57 (2000) 25-40
10. Athanasiadis A., Anderluh G., Macek P., and Turk D. Crystal structure of the soluble form of equinatoxin II, a pore-forming toxin from the sea anemone Actinia equina. Structure 9 (2001) 341-346
11. Avila A.D., de Acosta M.C., and Lage A. A new immunotoxin built by linking a hemolytic toxin to a monoclonal antibody specific for immature T lymphocytes. International Journal of Cancer 42 (1988) 568-571
12. Avila A.D., de Acosta M.C., and Lage A. A carcinoembryonic antigen-directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin. International Journal of Cancer 43 (1989) 926-929
13. Bayley H. Pore-forming proteins with built-in triggers and switches. Bioorganic Chemistry 23 (1995) 340-354
14. Belmonte G., Pederzolli C., Macek P., and Menestrina G. Pore formation by the sea anemone cytolysin equinatoxin II in red blood cells and model lipid membranes. Journal of Membrane Biology 131 (1993) 11-22
15. Casallanovo F., de Oliveira F.J., de Souza F.C., Ros U., Martinez Y., Penton D., Tejuca M., Martinez D., Pazos F., Pertinhez T.A., Spisni A., Cilli E.M., Lanio M.E., Alvarez C., and Schreier S. Model peptides mimic the structure and function of the N-terminus of the pore-forming toxin sticholysin II. Biopolymers 84 (2006) 169-180
16. Drechsler A., Potrich C., Sabo J.K., Frisanco M., Guella G., Dalla Serra M., Anderluh G., Separovic F., and Norton R.S. Structure and activity of the N-terminal region of the eukaryotic cytolysin equinatoxin II. Biochemistry 45 (2006) 1818-1828
17. Drobniewski F.A. Immunotoxins up to the present day. Bioscience Reports 9 (1989) 139-156
18. Drobniewski F.A., Watson G.J., Wawrzynczak E.J., Alouf J.E., and Thorpe P.E. A novel membrane-acting immunotoxin, the immunolysin, with therapeutic potential. Biochemical Society Transactions 20 (1992) 318S
19. Dunn R.D., Weston K.M., Longhurst T.J., Lilley G.G., Rivett D.E., Hudson P.J., and Raison R.L. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin. Immunotechnology 2 (1996) 229-240
20. Duvic M., Kuzel T.M., Olsen E.A., Martin A.G., Foss F.M., Kim Y.H., Heald P.W., Bacha P., Nichols J., and Liepa A. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma 2 (2002) 222-228
21. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer 2 (2002) 161-174
22. Gasanov S.E., Rael E.D., Gasanov N.E., and Vernon L.P. In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin. Cancer Immunology and Immunotherapy 41 (1995) 122-128
23. Ghetie V., and Vitetta E.S. Chemical construction of immunotoxins. Molecular Biotechnology 18 (2001) 251-268
24. Giraldi T., Ferlan I., and Romeo D. Antitumor activity of equinatoxin. Chemico-Biological Interactions 13 (1976) 199-203
25. Hinds M.G., Zhang W., Anderluh G., Hansen P.E., and Norton R.S. Solution structure of the eukaryotic pore-forming cytolysin equinatoxin II: implications for pore formation. Journal of Molecular Biology 315 (2002) 1219-1229
26. Hinman C.L., and Tang H.P. A membrane-lytic immunoconjugate selective for human tumor T-lymphocytes. International Journal of Immunopharmacology 20 (1998) 467-478
27. Hong Q., Gutierrez-Aguirre I., Barlic A., Malovrh P., Kristan K., Podlesek Z., Macek P., Turk D., Gonzalez-Manas J.M., Lakey J.H., and Anderluh G. Two-step membrane binding by equinatoxin II, a pore-forming toxin from the sea anemone, involves an exposed aromatic cluster and a flexible helix. Journal of Biological Chemistry 277 (2002) 41916-41924
28. Kem W.R. Sea anemone toxins: structure and action. In: Hessinger D.A. (Ed). The Biology of Nematocysts (1988), Academic Press, San Diego 375-405
29. Kreitman R.J. Immunotoxins in cancer therapy. Current Opinion in Immunology 11 (1999) 570-578
30. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., and Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. The New England Journal of Medicine 345 (2001) 241-247
31. Kristan K., Viero G., Macek P., Dalla Serra M., and Anderluh G. The Equinatoxin N-terminus is transferred across planar bilayers and helps to stabilise the transmembrane pore. The FEBS Journal 274 (2007) 539-550
32. Liu S., Aaronson H., Mitola D.J., Leppla S.H., and Bugge T.H. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proceedings of the National Academy of Sciences of the USA 100 (2003) 657-662
33. Liu S., Bugge T.H., and Leppla S.H. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. Journal of Biological Chemistry 276 (2001) 17976-17984
34. Liu S., Wang H., Currie B.M., Molinolo A., Leung H.J., Moayeri M., Basile J.R., Alfano R.W., Gutkind J.S., Frankel A.E., Bugge T.H., and Leppla S.H. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. Journal of Biological Chemistry 283 (2008) 529-540
35. Liu S.H., Netzel-Arnett S., Birkedal-Hansen H., and Leppla S.H. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Research 60 (2000) 6061-6067
36. Macek P., Belmonte G., Pederzolli C., and Menestrina G. Mechanism of action of equinatoxin II, a cytolysin from the sea anemone Actinia equina L. belonging to the family of actinoporins. Toxicology 87 (1994) 205-227
37. Mai J., Waisman D.M., and Sloane B.F. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochimica et Biophysica Acta - Biomembranes 1477 (2000) 215-230
38. Malovrh P., Barlic A., Podlesek Z., Menestrina G., Macek P., and Anderluh G. Structure-function studies of tryptophan mutants of equinatoxin II, a sea anemone pore-forming protein. Biochemical Journal 346 (2000) 223-232
39. Malovrh P., Viero G., Dalla Serra M., Podlesek Z., Lakey J.H., Macek P., Menestrina G., and Anderluh G. A novel mechanism of pore-formation: equinatoxin penetration of membrane by the N-terminal amphipathic region of equinatoxin. Journal of Biological Chemistry 278 (2003) 22678-22685
40. Mancheno J.M., Martin-Benito J., Martinez-Ripoll M., Gavilanes J.G., and Hermoso J.A. Crystal and electron microscopy structures of sticholysin II actinoporin reveal insights into the mechanism of membrane pore formation. Structure 11 (2003) 1319-1328
41. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., Jegasothy B., Wood G., Gordon M., Heald P., Oseroff A., Pinter-Brown L., Bowen G., Kuzel T., Fivenson D., Foss F., Glode M., Molina A., Knobler E., Stewart S., Cooper K., Stevens S., Craig F., Reuben J., Bacha P., and Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology 19 (2001) 376-388
42. Panchal R.G., Cusak E., Cheley S., and Bayley H. Tumor protease-activated, pore-forming toxins from a combinatorial library. Nature Biotechnology 14 (1996) 852-856
43. Pastan I., Hassan R., FitzGerald D.J., and Kreitman R.J. Immunotoxin treatment of cancer. Annual Review of Medicine 58 (2007) 221-237
44. Pederzolli C., Belmonte G., Dalla Serra M., Macek P., and Menestrina G. Biochemical and cytotoxic properties of conjugates of transferrin with equinatoxin II, a cytolysin from a sea anemone. Bioconjugate Chemistry 6 (1995) 166-173
45. Potrich C., Tomazzolli R., Dalla Serra M., Anderluh G., Malovrh P., Macek P., Menestrina G., and Tejuca M. Cytotoxic activity of a tumor protease-activated pore forming toxin. Bioconjugate Chemistry 16 (2005) 369-376
46. Potrich C., Viero G., Tejuca M., Anderluh G., Macek P., and Menestrina G. Construction of new immunotoxins by linking equinatoxin II to monoclonal antibodies via the biotin-avidin interaction. Cytotoxic effects on human tumor cells. Acta Biologica Slovenica 43 (2000) 47-51
47. Rono B., Romer J., Liu S., Bugge T.H., Leppla S.H., and Kristjansen P.E. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Molecular Cancer Therapeutics 5 (2006) 89-96
48. Soletti R.C., Pinto de Faria G., Vernal J., Terenzi H., Anderluh G., Borges H.L., Moura-Neto V., and Gabilan N.H. Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells. Anticancer Drugs 19 (2008) 517-525
49. Su Y., Ortiz J., Liu S., Bugge T.H., Singh R., Leppla S.H., and Frankel A.E. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice. Cancer Research 67 (2007) 3329-3336
50. Tejuca M., Anderluh G., Macek P., Alvarez C., Lanio M.E., Marcet R., Torres D., Sarracent J., Dalla Serra M., and Menestrina G. Antiparasite activity of sea anemone cytolysins on Giardia duodenalis and specific targeting with anti-Giardia antibodies. International Journal of Parasitology 29 (1999) 489-498
51. Tejuca M., Dalla Serra M., Alvarez C., Potrich C., and Menestrina G. Sizing the radius of the pore formed in erythrocytes and lipid vesicles by the toxin sticholysin I from the sea anemone Stichodactyla helianthus. Journal of Membrane Biology 183 (2001) 125-135
52. Tejuca M., Dalla Serra M., Ferreras M., Lanio M.E., and Menestrina G. The mechanism of membrane permeabilisation by sticholysin I, a cytolysin isolated from the venom of the sea anemone Stichodactyla helianthus. Biochemistry 35 (1996) 14947-14957
53. Tejuca M., Diaz I., Figueredo R., Roque L., Pazos F., Martinez D., Iznaga-Escobar N., Perez R., Alvarez C., and Lanio M.E. Construction of an immunotoxin with the pore forming protein StI and IOR C5, a monoclonal antibody against a colon cancer cell line. International Immunopharmacology 4 (2004) 731-744
54. Thrush G.R., Lark L.R., Clinchy B.C., and Vitetta E.S. Immunotoxins: an update. Annual Review of Immunology 14 (1996) 49-71
55. Walker B., and Bayley H. A pore-forming protein with a protease-activated trigger. Protein Engineering 7 (1994) 91-97
56. Wan L., Zeng L., Chen L., Huang Q., Li S., Lu Y., Li Y., Cheng J., and Lu X. Expression, purification, and refolding of a novel immunotoxin containing humanized single-chain fragment variable antibody against CTLA4 and the N-terminal fragment of human perforin. Protein Expression and Purification 48 (2006) 307-313
57. Zhang Y., Xiang L., Hassan R., Paik C.H., Carrasquillo J.A., Jang B.S., Le N., Ho M., and Pastan I. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clinical Cancer Research 12 (2006) 4695-4701